What Researchers Did
Researchers conducted a systematic review and meta-analysis of 24 randomized clinical trials involving 1,497 participants to evaluate the adverse effects of hyperbaric oxygen therapy (HBOT).
What They Found
Across 24 randomized clinical trials involving 1,497 participants, the hyperbaric oxygen therapy (HBOT) group experienced significantly more adverse effects (30.11%) compared to control groups (10.43%). Adverse reactions were more likely when chamber pressure exceeded 2.0 ATA, and increased attention to potential side effects is warranted if treatment courses exceed 10 sessions.
What This Means for Canadian Patients
Canadian patients undergoing hyperbaric oxygen therapy should be informed about potential adverse effects, which occurred in 30.11% of HBOT recipients in this review. They should discuss with their healthcare providers the risks associated with chamber pressures above 2.0 ATA and treatment courses longer than 10 sessions.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
Potential limitations include the heterogeneity of the included studies and reliance on reported data from primary trials.